Key result
Oral rapamycin cuts in-segment restenosis ~73% after bare-metal stenting versus no therapy.
Why the study?
Small observational studies suggested that oral rapamycin reduces angiographic restenosis after bare metal stent implantation, but randomized data were needed.
Does oral rapamycin plus diltiazem reduce angiographic restenosis and late loss in patients undergoing coronary bare-metal stent implantation?
RCT (n=100)
Unblinded
randomized
Does oral rapamycin plus diltiazem reduce angiographic restenosis and late loss in patients undergoing coronary bare-metal stent implantation?
Answers are grounded in this paper and cite their sources.
A 14-day course of oral rapamycin after bare-metal stent implantation significantly reduces angiographic restenosis and the need for repeat revascularization at 1 year.
OBJECTIVES: The purpose of this study was to assess the role of oral rapamycin in decreased restenosis after bare metal stent implantation. BACKGROUND: Small observational studies suggest that the administration of oral rapamycin reduces angiographic restenosis after bare metal stent implantation. METHODS: Between September 2003 and September 2004, 100 patients were randomized to either oral rapamycin (6-mg loading dose given 2.7 h before intervention followed by 3 mg/day for 14 days) plus diltiazem 180 mg/day or no therapy after the implantation of a coronary bare metal stent design. The primary study end point was incidence of angiographic binary restenosis and late loss at nine months. The secondary end points were target lesion revascularization, target vessel revascularization, and incidence of major adverse cardiovascular events at 1 year. RESULTS: Angiographic follow-up was completed in 87% of patients. In the rapamycin group, the drug was well tolerated (26% minor side effects) and was maintained in 96% of patients. At 9 months, the in-segment binary restenosis was reduced by 72% (11.6% rapamycin vs. 42.8% no-therapy group, p = 0.001) and the in-stent binary restenosis was reduced by 65% (12% rapamycin vs. 34.6% no-therapy group, p = 0.009). The in-segment late loss was also significantly reduced with oral therapy (0.66 vs. 1.13 mm, respectively; 43% reduction, p < 0.001). At 1 year, patients in the oral rapamycin group also showed a significantly lower incidence of target vessel revascularization (8.3% vs. 38%, respectively, p < 0.001), target lesion revascularization (7.6% vs. 37.2%, respectively, p < 0.001), and major adverse cardiovascular events (20% vs. 44%, respectively, p = 0.018). CONCLUSIONS: This randomized, controlled, and unblinded study showed that the administration of oral rapamycin during 14 days after stent implantation significantly reduces angiographic and clinical parameters of restenosis.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2006) conducted an RCT in Restenosis after bare-metal stent implantation (n=100). Oral rapamycin plus diltiazem vs. No therapy was evaluated on Incidence of angiographic binary restenosis and late loss at nine months (p=0.001). Oral rapamycin administered for 14 days after bare-metal stent implantation reduced in-segment binary restenosis at 9 months compared to no therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: